Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

被引：106

作者：

Huang, Min ^{[1
]}

O'Shaughnessy, Joyce ^{[2
]}

Zhao, Jing ^{[1
]}

Haiderali, Amin ^{[1
]}

Cortes, Javier ^{[3
,4
,5
]}

Ramsey, Scott D. ^{[6
,7
]}

Briggs, Andrew ^{[8
]}

Hu, Peter ^{[1
]}

Karantza, Vassiliki ^{[1
]}

Aktan, Gursel ^{[1
]}

Qi, Cynthia Z. ^{[9
]}

Gu, Chenyang ^{[10
]}

Xie, Jipan ^{[10
]}

Yuan, Muhan ^{[9
]}

Cook, John ^{[11
]}

Untch, Michael ^{[12
]}

Schmid, Peter ^{[13
]}

Fasching, Peter A. ^{[14
]}

机构：

[1] Merck & Co Inc, Kenilworth, NJ 07033 USA

[2] Baylor Univ, Med Ctr, Texas Oncol & US Oncol, Dallas, TX USA

[3] IOB Inst Oncol, Quironsalud Grp, Madrid, Spain

[4] IOB Inst Oncol, Quironsalud Grp, Barcelona, Spain

[5] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[6] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[7] Univ Washington, Seattle, WA 98195 USA

[8] London Sch Hyg & Trop Med, London, England

[9] Anal Grp Inc, Boston, MA USA

[10] Anal Grp Inc, Los Angeles, CA USA

[11] Complete HEOR Solut, N Wales, PA USA

[12] Helios Klinikum Berlin Buch, Dept Gynecol, Berlin, Germany

[13] Queen Mary Univ London, Barts Canc Inst, London, England

[14] Friedrich Alexander Univ Erlangen Nuremberg, Dept Gynecol & Obstet, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany

来源：

CANCER RESEARCH | 2020年 / 80卷 / 24期

关键词：

RECEIVED NEOADJUVANT CHEMOTHERAPY; POOLED ANALYSIS; DOSE-DENSE; PACLITAXEL; IMPACT; CYCLOPHOSPHAMIDE; DOXORUBICIN; SURROGATE; THERAPY; TRIAL;

D O I：

10.1158/0008-5472.CAN-20-1792

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pathologic complete response (pCR) following neoadjuvant therapy has been associated with improved event-free survival (EFS) and overall survival (OS) in early-stage breast cancer. The magnitude of this association varies by breast cancer subtype, yet further research focusing on subtype-specific populations is limited. Here we provide an updated and comprehensive evaluation of the association between pCR and survival outcomes in triple-negative breast cancer (TNBC). A literature review identified neoadjuvant studies, including clinical trials, real-world cohort studies, and studies that pooled multiple trials or cohorts, which reported EFS/OS results by pCR in patients with early-stage TNBC. Meta-analyses were performed to evaluate the association between pCR and EFS/OS and to predict long-term survival outcomes based on pCR status. Sensitivity analyses were conducted to assess the impact of cross-study variations. Twenty-five studies with over 4,000 patients with TNBC were identified. A synthesis of evidence from these studies suggested substantial improvement in EFS and OS for pCR versus non-pCR [EFS HR (95% confidence interval): 0.24 (0.20-0.29); OS: 0.19 (0.15-0.24)]; consistent results were reported in sensitivity analyses. Collectively, our findings suggest that adjuvant therapy is associated with improved EFS/OS in patients with TNBC who received neoadjuvant therapy, regardless of pCR status.

引用

页码：5427 / 5434

页数：8

共 64 条

[1]

[Anonymous], 2014, Draft guideline on the role of the pathological complete response as an endpoint in neoadjuvant breast cancer studies

[2] Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies [J].